10 / PRNewswire / -- Centocor Ortho Biotech Products , L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration ( FDA ) regarding its Supplemental New Drug Application ( sNDA ) for DOXIL ( doxorubicin HCI liposome injection ) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer .